Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats

Bricon, Thierry Le; Gugins, S.; Cynober, Luc; Baracos, Vickie E.

doi:10.1016/0026-0495(95)90040-3

Cited by 61 publications

(69 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A series of published studies showed different doses of MTX and administration routes used in experimental models 21,[23][24][25][26][27] . An intraperitoneal administration route was selected since it is frequently used in animals and allows rapid absorption 21,24,25 .…”

Section: Discussionmentioning

confidence: 99%

“…An intraperitoneal administration route was selected since it is frequently used in animals and allows rapid absorption 21,24,25 .…”

Section: Discussionmentioning

confidence: 99%

“…It is difficult to directly compare these doses with those used clinically, because of the relatively elevated rat metabolism. The presence of a characteristic response to each drug suggests the need for further study to describe the effects of polychemotherapy 24 .…”

Section: Discussionmentioning

confidence: 99%

“…They were divided into four groups of 25 animals. Group A: control, saline solution (1 mL/week), with the first dose administered two hours before surgery; Group B: DEX (0,15 mg/Kg) (Decadron ® , Prodome, Campinas, Brazil), single dose, immediately after surgery 23 ; Group C: MTX low dose (3mg/ Kg -adjusted with normal saline solution to a volume of 1 mL), weekly (Miantrex ® , Pfizer, Guarulhos, Brazil), with the first dose administered two hours before surgery 21 ; Group D: MTX high dose (30 mg/Kg -adjusted with normal saline solution to a volume of 1 mL), single dose administered two hours before surgery 24 .…”

Section: Methodsmentioning

confidence: 99%

“…Another comparative study evaluated a single-dose injection of 30 mg/Kg of MTX in tumorbearing rats and observed that it exhibited antitumor activity 24 .…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Facial symmetry evaluation after experimentally displaced condylar process fracture in methotrexate treated rats

Cavalcanti¹,

Corrêa

Luz³

2012

Acta Cir. Bras.

View full text Add to dashboard Cite

PURPOSE: To investigate the facial symmetry of high and low dose methotrexate (MTX) treated rats submitted to experimentally displaced mandibular condyle fracture through the recording of cephalometric measurements. METHODS: One hundred male Wistar rats underwent surgery using an experimental model of right condylar fracture. Animals were divided into four groups: A - saline solution (1mL/week); B - dexamethasone (DEX) (0,15mg/Kg); C - MTX low dose (3 mg/Kg/week); D - MTX high dose (30 mg/Kg). Animals were sacrificed at 1, 7, 15, 30 and 90 days postoperatively (n=5). Body weight was recorded. Specimens were submitted to axial radiographic incidence, and cephalometric mensurations were made using a computer system. Linear measurements of skull and mandible, as well as angular measurements of mandibular deviation were taken. Data were subjected to statistical analyses among the groups, periods of sacrifice and between the sides in each group (α=0.05). RESULTS: Animals regained body weight over time, except in group D. There was reduction in the mandibular length and also changes in the maxilla as well as progressive deviation in the mandible in relation to the skull basis in group D. CONCLUSION: Treatment with high dose methotrexate had deleterious effect on facial symmetry of rats submitted to experimentally displaced condylar process fracture.

show abstract

Section: Discussionmentioning

confidence: 99%

“…An intraperitoneal administration route was selected since it is frequently used in animals and allows rapid absorption 21,24,25 .…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…Another comparative study evaluated a single-dose injection of 30 mg/Kg of MTX in tumorbearing rats and observed that it exhibited antitumor activity 24 .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Facial symmetry evaluation after experimentally displaced condylar process fracture in methotrexate treated rats

Cavalcanti¹,

Corrêa

Luz³

2012

Acta Cir. Bras.

View full text Add to dashboard Cite

show abstract

Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism

Barreto

Couch

et al. 2019

J cachexia sarcopenia muscle

181

223

View full text Add to dashboard Cite

Background Cancer cachexia is a metabolic disorder involving perturbed energy balance and altered mitochondrial function. Chemotherapy is a primary treatment option for many types of cancer, but there is substantial evidence that some chemotherapeutic agents can also lead to the development and progression of cachexia. In this study, we apply a comprehensive and systems level metabolomics approach to characterize the metabolic perturbations in murine models of cancer‐induced and chemotherapy‐induced cachexia. Knowledge of the unique pathways through which cancer and chemotherapy drive cachexia is necessary in order to develop effective treatments. Methods The murine Colon26 (C26) adenocarcinoma xenograft model was used to study the metabolic derangements associated with cancer‐induced cachexia. In vivo administration of Folfiri (5‐fluorouracil, irinotecan, and leucovorin) was used to model chemotherapy‐induced cachexia. Comprehensive metabolic profiling was carried out using both nuclear magnetic resonance‐based and mass spectrometry‐based platforms. Analyses included plasma, muscle, and liver tissue to provide a systems level profiling. Results The study involved four groups of CD2F1 male mice ( n = 4–5), including vehicle treated (V), C26 tumour hosts (CC), Folfiri treated (F), and C26 tumour hosts treated with Folfiri (CCF). Significant weight loss including skeletal muscle was observed for each of the experimental groups with the tumour hosts showing the most dramatic change (−3.74 g vs. initial body weight in the CC group). Skeletal muscle loss was evident in all experimental groups compared with V, with the CCF combination resulting in the most severe depletion of quadriceps mass (−38% vs. V; P < 0.001). All experimental groups were characterized by an increased systemic glucose demand as evidenced by decreased levels of circulating glucose (−47% in CC vs. V; P < 0.001) and depletion of liver glucose (−51% in CC vs. V; P < 0.001) and glycogen (−74% in CC vs. V; P < 0.001). The cancer‐induced and chemotherapy‐induced cachexia models displayed unique alterations in flux through the tricarboxylic acid cycle and β‐oxidation pathways. Cancer‐induced cachexia was uniquely characterized by a dramatic elevation in low‐density lipoprotein particles (+6.9‐fold vs. V; P < 0.001) and a significant increase in the inflammatory marker, GlycA (+33% vs. V; P < 0.001). Conclusions The results of this study demonstrated for the first time that cancer‐induced and chemotherapy‐induced cachexia is characterized by a number of distinct metabolic derangements. Effective therapeutic interventions for cancer‐induced and chemotherapy‐induced cachexia must take into account the specific metabolic de...

show abstract

Cachectic muscle wasting in acute myeloid leukaemia: a sleeping giant with dire clinical consequences

Campelj

Timpani

Rybalka

2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Acute myeloid leukaemia (AML) is a haematological malignancy with poor survival odds, particularly in the older (>65 years) population, in whom it is most prevalent. Treatment consists of induction and consolidation chemotherapy to remit the cancer followed by potentially curative haematopoietic cell transplantation. These intense treatments are debilitating and increase the risk of mortality. Patient stratification is used to mitigate this risk and considers a variety of factors, including body mass, to determine whether a patient is suitable for any or all treatment options. Skeletal muscle mass, the primary constituent of the body lean mass, may be a better predictor of patient suitability for, and outcomes of, AML treatment. Yet skeletal muscle is compromised by a variety of factors associated with AML and its clinical treatment consistent with cachexia, a life‐threatening body wasting syndrome. Cachectic muscle wasting is associated with both cancer and anticancer chemotherapy. Although not traditionally associated with haematological cancers, cachexia is observed in AML and can have dire consequences. In this review, we discuss the importance of addressing skeletal muscle mass and cachexia within the AML clinical landscape in view of improving survivability of this disease.

show abstract

Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats

Cited by 61 publications

References 23 publications

Facial symmetry evaluation after experimentally displaced condylar process fracture in methotrexate treated rats

Facial symmetry evaluation after experimentally displaced condylar process fracture in methotrexate treated rats

Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism

Cachectic muscle wasting in acute myeloid leukaemia: a sleeping giant with dire clinical consequences

Contact Info

Product

Resources

About